Trials / Completed
CompletedNCT03708887
The Effect of Omega-3 FA on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Patients
Double-blind and Placebo-controlled Study on Intervention Effect of n-3 Fatty Acids on Glucose and Lipid Homeostasis Disorders in Obese/Diabetic Populations
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 415 (actual)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A double-blind and placebo-controlled study is conducted in the current human study. The purpose of this study is to investigate the effects of n-3 PUFA intervention on glucose and lipid homeostasis in Chinese diabetic/obese patients.
Detailed description
Approximately 450 diabetic and 450 obese patients will be enrolled from Lanxi in China. They will be randomly assigned into one of the following three groups: Omega-3 fatty acids capsules (1.5 g/d); or omega-3 fatty acids capsules (3 g/d); or placebo capsules. Blood, feces and urine samples will be collected before and after treatment. Glucose and lipid parameters will be measured. Diabetes comorbidities and complications will also be assessed. This study will also explore the new mechanisms of n-3 PUFAs on improving glucose and lipid homeostasis and other outcomes based on multi-omics and establish a model for precision intervention.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Low dose omega-3 fatty acid supplementation | Omega-3 fatty acids capsules, 1.5 g/d by mouth for 1 year |
| DRUG | High dose omega-3 fatty acid supplementation | Omega-3 fatty acids capsules, 3 g/d by mouth for 1 year |
| DRUG | Control drug | Matching placebo capsules,3 g/d by mouth for 1 year |
Timeline
- Start date
- 2020-10-10
- Primary completion
- 2022-01-02
- Completion
- 2022-02-28
- First posted
- 2018-10-17
- Last updated
- 2024-07-12
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03708887. Inclusion in this directory is not an endorsement.